REG - Angle PLC - Director/PDMR shareholding

AngleAnnouncement

09/02/2023 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230209:nRSI4936Pa&default-theme=true

RNS Number : 4936P  Angle PLC  09 February 2023

 

09 February 2023

 

For immediate release

 

ANGLE plc ("the Company")

 

Director/PDMR shareholding

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company,
announces that, on 09 February 2023, it has been notified that Andrew Newland,
Chief Executive Officer, purchased 125,000 ordinary shares of 10 pence each
("Ordinary Shares") at a price of 28.75 pence each.

 

The Company was also notified that Ian Griffiths, Finance Director, purchased
30,000 Ordinary Shares via his self-invested personal pension (SIPP) at 29.175
pence each. Ian Griffiths also sold from his personal dealing account and
re-purchased into his SIPP 37,500 Ordinary Shares at a price of 29.25 pence
and 29.50 pence respectively.

 

Further details are set out below:

 

 1.   Details of the person discharging managerial responsibilities/person closely
      associated
 (a)  Name                                             Andrew Newland
 2.   Reason for the notification
 (a)  Position/status                                  Chief Executive Officer
 (b)  Initial notification/ Amendment                  Initial notification
 3.   Details of the issuer
 (a)  Name                                             ANGLE plc
 (b)  LEI                                              213800BY11K6W3NMS374
 4.   Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 (a)  Description of the Financial Instrument          Ordinary shares of 10 pence each
 (b)  Identification code of the Financial Instrument  ISIN: GB0034330679
 (c)  Nature of the transaction                        Acquisition of Ordinary Shares
 (d)  Price(s) and volume(s)                           Price(s)                    Volume(s)
                                                       28.75 pence                 125,000

 (e)  Aggregated information                           As above

 (f)  Date of the transaction                          09 February 2023
 (g)  Place of the transaction                         London Stock Exchange XLON

 

 2.   Details of the person discharging managerial responsibilities/person closely
      associated
 (a)  Name                                             Ian Griffiths
 2.   Reason for the notification
 (a)  Position/status                                  Finance Director
 (b)  Initial notification/ Amendment                  Initial notification
 3.   Details of the issuer
 (a)  Name                                             ANGLE plc
 (b)  LEI                                              213800BY11K6W3NMS374
 4.   Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 (a)  Description of the Financial Instrument          Ordinary shares of 10 pence each
 (b)  Identification code of the Financial Instrument  ISIN: GB0034330679
 (c)  Nature of the transaction                        Sale from dealing account and matching purchase into SIPP account of Ordinary
                                                       Shares
 (d)  Price(s) and volume(s)                           Price(s)                                 Volume(s)
                                                       29.25 pence                              37,500

                                                       29.50 pence                              37,500

 (e)  Aggregated information                           As above

 (f)  Date of the transaction                          09 February 2023
 (g)  Place of the transaction                         London Stock Exchange XLON

 

 

 3.   Details of the person discharging managerial responsibilities/person closely
      associated
 (a)  Name                                             Ian Griffiths
 2.   Reason for the notification
 (a)  Position/status                                  Finance Director
 (b)  Initial notification/ Amendment                  Initial notification
 3.   Details of the issuer
 (a)  Name                                             ANGLE plc
 (b)  LEI                                              213800BY11K6W3NMS374
 4.   Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 (a)  Description of the Financial Instrument          Ordinary shares of 10 pence each
 (b)  Identification code of the Financial Instrument  ISIN: GB0034330679
 (c)  Nature of the transaction                        Acquisition of Ordinary Shares
 (d)  Price(s) and volume(s)                           Price(s)                    Volume(s)
                                                       29.175 pence                30,000

 (e)  Aggregated information                           As above

 (f)  Date of the transaction                          09 February 2023
 (g)  Place of the transaction                         London Stock Exchange XLON

 

 

 

For further information:

 

 ANGLE plc                                   +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Andrew Holder, Head of Investor Relations

 Berenberg (NOMAD & Joint Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 Jefferies (Joint Broker)                    +44 (0) 20 7029 8000

 Thomas Bective, Shaam Vora

 FTI Consulting

 Simon Conway, Ciara Martin                  +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                    +1 (212) 850 5624

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a
regulatory information service, this information is considered to be in the
public domain.

 

 

Notes for editors

About ANGLE plc www.angleplc.com (http://www.angleplc.com)

ANGLE is a world leading liquid biopsy company with sample-to-answer
solutions. ANGLE's proven patent protected circulating tumor cell (CTC)
harvesting technology is known as the Parsortix® system.

ANGLE's Parsortix® system is FDA cleared for its intended use in metastatic
breast cancer and is currently the first and only FDA cleared medical device
to harvest intact circulating cancer cells from blood.

Intended use

The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich
circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes
from patients diagnosed with metastatic breast cancer. The system employs a
microfluidic chamber (a Parsortix cell separation cassette) to capture cells
of a certain size and deformability from the population of cells present in
blood. The cells retained in the cassette are harvested by the Parsortix PC1
system for use in subsequent downstream assays. The end user is responsible
for the validation of any downstream assay. The standalone device, as
indicated, does not identify, enumerate or characterize CTCs and cannot be
used to make any diagnostic/prognostic claims for CTCs, including monitoring
indications or as an aid in any disease management and/or treatment decisions.

The Parsortix system enables a liquid biopsy (a simple blood test) to be used
to provide the circulating metastatic breast cancer cells to the user in a
format suitable for multiple types of downstream analyses. The system is based
on a microfluidic device that captures cells based on a combination of their
size and compressibility. The system is epitope independent and can capture
all phenotypes of CTCs (epithelial, mesenchymal and EMTing CTCs) as well as
CTC clusters in a viable form (alive). CTCs harvested from the system enable a
complete picture of a cancer to be seen; as being an intact cell they allow
DNA, RNA and protein analysis as well as cytological and morphological
examination and may provide comparable analysis to a tissue biopsy in
metastatic breast cancer. Because CTC analysis is a non-invasive process,
unlike tissue biopsy, it can be repeated as often as needed. This is important
because cancer develops and changes over time and there is a clear medical
need for up-to-date information on the status of a patient's tumor. In
addition, the live CTCs harvested by the Parsortix system can be cultured,
which offers the potential for testing tumor response to drugs outside the
patient.

The Parsortix technology is the subject of 26 granted patents in Europe, the
United States, China, Australia, Canada, India, Japan and Mexico with three
extensive families of patents are being progressed worldwide.

In the United States, the Parsortix® PC1 system has received a Class II
Classification from FDA for use with metastatic breast cancer patients. FDA
clearance is seen as the global gold standard. ANGLE's Parsortix system is the
first ever FDA cleared system for harvesting CTCs for subsequent analysis.
ANGLE has applied the IVD CE Mark to the same system for the same intended use
in Europe.

ANGLE has also completed three separate 200 subject clinical studies under a
programme designed to develop an ovarian cancer pelvic mass triage test, with
the results showing best in class accuracy (AUC-ROC) of 95.4% with sensitivity
of 90% and specificity of 93%. This excellent clinical result demonstrates the
utility of cells harvested by the Parsortix system, which the Company believes
is the "best sample" for liquid biopsy analysis as it recovers intact, living
cancer cells that are involved in the progression of the disease providing
prospective information.

ANGLE has established formal collaborations with world-class cancer centres
and major corporates such as Abbott, Philips and QIAGEN, and works closely
with leading CTC translational research customers. These Key Opinion Leaders
(KOLs) are working to identify applications with medical utility (clear
benefit to patients), and to secure clinical data that demonstrates that
utility in patient studies. The body of evidence as to the benefits of the
Parsortix system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with 76
peer-reviewed publications and numerous publicly available posters from 33
independent cancer centres, available on our website.

 

ANGLE has established clinical services laboratories in the UK and the United
States to accelerate commercialisation of the Parsortix system and act as
demonstrators to support product development. The laboratories offer services
globally to pharmaceutical and biotech customers for use of Parsortix in
cancer drug trials and, once the laboratories are accredited and tests
validated, will provide Laboratory Developed Tests (LDTs) for patient
management.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHZKLFBXLLZBBB